Insmed received clearance from the FDA for the investigational new drug (IND) application for INS1201, an intrathecally delivered gene therapy for patients with Duchenne muscular dystrophy (DMD). More than 10 new initatives leveraging AI to transform drug discovery, development, and commercialization N...
Insmed received clearance from the FDA for the investigational new drug (IND) application for INS1201, an intrathecally delivered gene therapy for patients with Duchenne muscular dystrophy (DMD). More than 10 new initatives leveraging AI to transform drug discovery, development, and commercialization N...